focusing on cancer indications with the greatest medical need for new treatments
Featured News & Events
Jul 12, 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Jul 6, 2021
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021
Jun 28, 2021
Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes
Our Clinical Programs
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.